What is the 13F Pro Quality Score for NERV?

13F Pro ranks Minerva Neurosciences, Inc. (NERV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NERV's current score at https://13fpro.ai/research/NERV (free sign-up required for the full ranking).

Which hedge funds own the most NERV stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NERV include FEDERATED HERMES,, Vivo Capital,, JANUS HENDERSON GROUP PLC. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NERV as soon as new 13F filings post.

Where does 13F Pro source NERV data?

All Minerva Neurosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Minerva Neurosciences, Inc. files with the SEC under CIK 1598646. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NERV in?

Minerva Neurosciences, Inc. (NERV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NERV research updated on 13F Pro?

NERV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Minerva Neurosciences, Inc.(NERV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1598646 NERV stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $41.2M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NERV Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Minerva Neurosciences, Inc. (NERV), a Healthcare sector company. NERV is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $41.2m in revenue. Based on the latest XBRL financial filings (Q1 2026), Minerva Neurosciences, Inc. reports net income of $-125.4M, free cash flow of $-5.4M. Top institutional holders of NERV by reported 13-F value include FEDERATED HERMES,, Vivo Capital,, JANUS HENDERSON GROUP PLC, based on the most recent SEC filings. NERV trades on the Nasdaq exchange and files with the SEC under CIK 1598646. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NERV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Minerva Neurosciences, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-125.4M

Free Cash Flow

Q1 2026

$-5.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$0.00FY 2024

FY20 $41.2MFY21 $0.00FY23 $0.00FY24 $0.00

Net Income

+104.8% YoY

$1.4MFY 2024

FY20 $1.9MFY21 $-49.9MFY23 $-30.0MFY24 $1.4M

Operating Income

+5.5% YoY

$-21.8MFY 2024

FY20 $1.8MFY21 $-45.4MFY23 $-23.1MFY24 $-21.8M

EPS (Diluted)

+104.1% YoY

$0.19FY 2024

FY20 $0.05FY21 $-9.35FY23 $-4.61FY24 $0.19

Total Assets

-34.7% YoY

$37.1MFY 2024

FY20 $57.6MFY21 $77.1MFY23 $56.9MFY24 $37.1M

Op. Cash Flow

-32.2% YoY

$-19.6MFY 2024

FY20 $-33.8MFY21 $-24.6MFY23 $-14.8MFY24 $-19.6M

Metric	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019	FY 2017
Revenue	$0.00	$0.00	$0.00 -100.0%	$41.2M	$0.00	$0.00
Net Income	$1.4M +104.8%	$-30.0M +39.9%	$-49.9M -2671.4%	$1.9M +102.7%	$-72.2M -129.0%	$-31.5M
Operating Income	$-21.8M +5.5%	$-23.1M +49.0%	$-45.4M -2556.5%	$1.8M +102.4%	$-75.9M -84.3%	$-41.2M
EPS (Diluted)	$0.19 +104.1%	$-4.61 +50.7%	$-9.35 -18800.0%	$0.05 +102.7%	$-1.85	—
Total Assets	$37.1M -34.7%	$56.9M -26.2%	$77.1M +33.8%	$57.6M -25.6%	$77.5M -57.8%	$183.7M
Operating Cash Flow	$-19.6M -32.2%	$-14.8M +39.9%	$-24.6M +27.3%	$-33.8M +22.1%	$-43.4M -1504.3%	$3.1M

AI Insight: NERV Financial Trends

NERV posted a massive $284M net loss in Q4 2025, driving equity deeply negative to -$254M by Q1 2026.

• Net losses accelerated dramatically from -$3M in Q3 2025 to -$284M in Q4 2025, then -$125M in Q1 2026.

• Equity deteriorated sharply from -$35M in Q3 2025 to -$254M in Q1 2026.

• Operating losses widened from -$3M in Q3 2025 to -$17M in Q1 2026.

⚠ Company has no revenue stream and continues burning cash with deeply negative equity position.

⚠ Operating cash flow remained consistently negative at -$3M to -$5M across recent quarters.

AI Insight: NERV Ratio Trends

ROA improved steadily from -71.2% in Q2 2024 to -39.1% in Q3 2025, but limited data makes trend assessment difficult.

• ROA showed consistent improvement from -71.2% in Q2 2024 to -39.1% in Q3 2025, narrowing losses by 32pp.

⚠ Most profitability and efficiency metrics unavailable, limiting visibility into operational performance trends.

⚠ No ROA data available for Q4 2025 and Q1 2026, breaking the improvement trend visibility.

Get alerted when NERV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Minerva Neurosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NERV

FEDERATED HERMES, INC.
$30.8M5,113,224 sh
Vivo Capital, LLC
$26.0M4,322,747 sh
JANUS HENDERSON GROUP PLC
$25.9M4,294,259 sh
BALYASNY ASSET MANAGEMENT L.P.
$25.7M4,258,600 sh
Logos Global Management LP
$19.4M3,215,000 sh
FARALLON CAPITAL MANAGEMENT LLC
$14.2M2,365,000 sh
Foresite Capital Management VI LLC
$12.0M1,986,600 sh
VANGUARD CAPITAL MANAGEMENT LLC
$11.1M1,845,831 sh
Spruce Street Capital LP
$10.0M1,655,500 sh
Ally Bridge Group (NY) LLC
$10.0M1,655,500 sh

Fund	Value	Shares
FEDERATED HERMES, INC.	$30.8M	5,113,224
Vivo Capital, LLC	$26.0M	4,322,747
JANUS HENDERSON GROUP PLC	$25.9M	4,294,259
BALYASNY ASSET MANAGEMENT L.P.	$25.7M	4,258,600
Logos Global Management LP	$19.4M	3,215,000
FARALLON CAPITAL MANAGEMENT LLC	$14.2M	2,365,000
Foresite Capital Management VI LLC	$12.0M	1,986,600
VANGUARD CAPITAL MANAGEMENT LLC	$11.1M	1,845,831
Spruce Street Capital LP	$10.0M	1,655,500
Ally Bridge Group (NY) LLC	$10.0M	1,655,500

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NERV on your watchlist

Track score changes the day Minerva Neurosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NERV a good stock to buy?

13F Pro's AI-powered analysis of Minerva Neurosciences, Inc. (NERV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NERV are available on the NERV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NERV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NERV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Minerva Neurosciences, Inc.'s investment landscape.